These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 10996837)

  • 21. Rituximab (chimeric anti-CD20 antibody) for posttransplant lymphoproliferative disorder after solid organ transplantation in adults: long-term experience from a single center.
    Jain AB; Marcos A; Pokharna R; Shapiro R; Fontes PA; Marsh W; Mohanka R; Fung JJ
    Transplantation; 2005 Dec; 80(12):1692-8. PubMed ID: 16378063
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Monotherapy with the anti-CD20 monoclonal antibody rituximab in a kidney transplant recipient with posttransplant lymphoproliferative disease.
    Pham PT; Wilkinson AH; Gritsch HA; Pham PC; Miller JM; Lassman CR; Danovitch GM
    Transplant Proc; 2002 Jun; 34(4):1178-81. PubMed ID: 12072308
    [No Abstract]   [Full Text] [Related]  

  • 23. Epstein-Barr virus-associated post-transplant lymphoproliferative disorders presented as interstitial pneumonia; successful recovery with rituximab.
    Kunitomi A; Arima N; Ishikawa T
    Haematologica; 2007 Apr; 92(4):e49-52. PubMed ID: 17562592
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prospective phase II trial of extended treatment with rituximab in patients with B-cell post-transplant lymphoproliferative disease.
    González-Barca E; Domingo-Domenech E; Capote FJ; Gómez-Codina J; Salar A; Bailen A; Ribera JM; López A; Briones J; Muñoz A; Encuentra M; de Sevilla AF; ; ;
    Haematologica; 2007 Nov; 92(11):1489-94. PubMed ID: 18024397
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Post-transplant lymphoproliferative disease in children following solid organ transplant and rituximab--the final answer?
    Gross TG
    Pediatr Transplant; 2007 Sep; 11(6):575-7. PubMed ID: 17663676
    [No Abstract]   [Full Text] [Related]  

  • 26. Multicenter analysis of 80 solid organ transplantation recipients with post-transplantation lymphoproliferative disease: outcomes and prognostic factors in the modern era.
    Evens AM; David KA; Helenowski I; Nelson B; Kaufman D; Kircher SM; Gimelfarb A; Hattersley E; Mauro LA; Jovanovic B; Chadburn A; Stiff P; Winter JN; Mehta J; Van Besien K; Gregory S; Gordon LI; Shammo JM; Smith SE; Smith SM
    J Clin Oncol; 2010 Feb; 28(6):1038-46. PubMed ID: 20085936
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Anti-CD20 antibody (rituximab) administration in patients with late occurring lymphomas after solid organ transplant.
    Dotti G; Rambaldi A; Fiocchi R; Motta T; Torre G; Viero P; Gridelli B; Barbui T
    Haematologica; 2001 Jun; 86(6):618-23. PubMed ID: 11418370
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Treatment of post-transplant lymphoproliferative disease with rituximab monoclonal antibody after lung transplantation.
    Cook RC; Connors JM; Gascoyne RD; Fradet G; Levy RD
    Lancet; 1999 Nov; 354(9191):1698-9. PubMed ID: 10568575
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Successful prolonged rituximab treatment for post-transplant lymphoproliferative disorder following living donor liver transplantation in a child.
    Hayashida M; Ogita K; Matsuura T; Takahashi Y; Nishimoto Y; Ohga S; Hara T; Soejima Y; Taketomi A; Maehara Y; Kohashi K; Tsuneyoshi M; Taguchi T
    Pediatr Transplant; 2007 Sep; 11(6):671-5. PubMed ID: 17663692
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Anti-CD20 monoclonal antibody for post-transplant lymphoproliferative disorders.
    Faye A; Van Den Abeele T; Peuchmaur M; Mathieu-Boue A; Vilmer E
    Lancet; 1998 Oct; 352(9136):1285. PubMed ID: 9788467
    [No Abstract]   [Full Text] [Related]  

  • 31. PTLD treatment: reducing the chemotherapy burden through addition of rituximab.
    Dharnidharka VR; Gupta S
    Pediatr Transplant; 2010 Feb; 14(1):10-1. PubMed ID: 20078838
    [No Abstract]   [Full Text] [Related]  

  • 32. Prognostic factors in patients with post-transplant lymphoproliferative disorders (PTLD) in the rituximab era.
    Ghobrial IM; Habermann TM; Ristow KM; Ansell SM; Macon W; Geyer SM; McGregor CG
    Leuk Lymphoma; 2005 Feb; 46(2):191-6. PubMed ID: 15621801
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Post-transplant lymphoproliferative disease in pediatric solid organ transplant recipients.
    Wistinghausen B; Gross TG; Bollard C
    Pediatr Hematol Oncol; 2013 Sep; 30(6):520-31. PubMed ID: 23802715
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Role of chemotherapy and rituximab for treatment of posttransplant lymphoproliferative disorder in solid organ transplantation.
    Lee JJ; Lam MS; Rosenberg A
    Ann Pharmacother; 2007 Oct; 41(10):1648-59. PubMed ID: 17848421
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Anti-CD20 monoclonal antibody (Rituximab) treatment for Epstein-Barr virus-associated, B-cell lymphoproliferative disease in pediatric liver transplant recipients.
    Serinet MO; Jacquemin E; Habes D; Debray D; Fabre M; Bernard O
    J Pediatr Gastroenterol Nutr; 2002 Apr; 34(4):389-93. PubMed ID: 11930095
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Monoclonal antibody therapy for posttransplant lymphoproliferative disorders.
    Habermann TM
    Liver Transpl; 2000 Sep; 6(5):657-8. PubMed ID: 10980069
    [No Abstract]   [Full Text] [Related]  

  • 37. Posttransplant lymphoproliferative disease.
    Soltys K; Green M
    Pediatr Infect Dis J; 2005 Dec; 24(12):1107-8. PubMed ID: 16371875
    [No Abstract]   [Full Text] [Related]  

  • 38. Post-transplant lymphoproliferative disorders in children: the role of chemotherapy in the era of rituximab.
    Gallego S; Llort A; Gros L; Sanchez de Toledo J; Bueno J; Moreno A; Nieto J; Sanchez de Toledo J
    Pediatr Transplant; 2010 Feb; 14(1):61-6. PubMed ID: 19344338
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Bone marrow involvement in patients with posttransplant lymphoproliferative disorders: incidence and prognostic factors.
    Montanari F; O'Connor OA; Savage DG; Zain JM; Venkatraman S; McCormick EK; Crook MT; Tsao L; Sevilla DW; Bhagat G; Alobeid B
    Hum Pathol; 2010 Aug; 41(8):1150-8. PubMed ID: 20381113
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Bone marrow involvement by lymphoproliferative disorders after solid-organ transplant.
    Akar Özkan E; Özdemir BH; Yılmaz Akçay E; Terzi A; Karakuş S; Haberal M
    Exp Clin Transplant; 2015 Apr; 13 Suppl 1():183-7. PubMed ID: 25894151
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.